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The anaphylatoxin C5a, generated by activation of the innate immunity complement component C5, is a potent 
protein fragment. Binding of C5a to the guanine nucleotide-
binding protein (G-protein)-coupled C5a receptor (C5aR) 
present in immune-inflammatory cells, including monocytes, 
macrophages, neutrophils, and T cells, leads to proinflammatory 
activation. C5a exerts its effect by activating the C5aR.1 The 
C5aR, also known as complement component 5aR-1 (C5AR1) 
or cluster of differentiation 88 (CD88), belongs to the rhodopsin-
like receptor superfamily, characterized by 7 hydrophobic, 
transmembrane helical regions connected by 3 extracellular 
and 3 intracellular loops.2–6 Among the innate immune 
components, C5, C5a, and C5aR are abundant and suggested 
to play critical roles in atherogenesis.7,8 Atherosclerosis is 
increasingly recognized as a complex chronic inflammatory 
disease of the arterial walls,9–11 as evidenced by the presence 
of inflammatory cells, activated immune cells, and cytokines 
in lesions, all of which indicate involvement of the immune 
system.12 Monocyte-to-macrophage differentiation and low–
density lipoprotein (LDL) oxidation play a pivotal role in early 
atherogenesis. Macrophages are key players in many aspects of 
human physiology and disease, including atherosclerosis. By 
taking up modified LDL (oxidized or acetylated), monocyte-
derived macrophages are turned into fat-loaded macrophages 
residing in the vessel wall, furthering the local inflammatory 
response and leading to progression of the atherosclerotic 
plaque. Both innate and adaptive immunities play roles in 
various stages of atherosclerosis. The binding of C5a to the 
C5aR is postulated to occur via a 2-site binding mechanism.13 
The basic core of C5a is thought to interact with acidic residues 
in the receptor amino (N)-terminus,14 whereas the carboxyl 
(C)-terminal domain of C5a binds in a pocket formed by 
largely hydrophobic residues within the transmembrane helices 
(cylinders 1–7) of the C5aR.15 In addition, residues between 
1 and 35 in the N-terminal domain of C5aR are essential for 
the interaction with the chemotaxis inhibitory protein of 
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Objective—The goal of this study was to assess whether immunization of Ldlrtm1Her Apobtm2SgyJ mice with 2 peptides located at 
the N-terminus of the C5a receptor (C5aR), either alone or in combination, is effective in reducing atherosclerotic lesions.
Methods and Results—Five- to 6-week-old female Ldlrtm1HerApobtm2SgyJ mice were immunized using a repetitive 
immunization multiple sites strategy with keyhole limpet hemocyanin-conjugated peptides derived from the C5aR, either 
alone (designated as C5aR-P1 [aa 1–21] and C5aR-P2 [aa 19–31]) or in combination (designated as C5aR-P1+C5aR-P2). 
Mice were fed a high-fat diet for 10 weeks. Lesions were evaluated histologically; local and systemic immune responses 
were analyzed by immunohistochemistry of aorta samples and cytokine measurements in plasma samples and splenocyte 
supernatants. Immunization of Ldlrtm1HerApobtm2SgyJ mice with these peptides elicited high concentrations of antibodies 
against each peptide. Immunization with the single peptide inhibited plaque development. Combined inoculation with 
C5aR-P1+C5aR-P2 had an additive effect on reducing the lesion in the aorta sinus and descending aortas when compared 
with controls. This effect correlated with cellular infiltration and cytokine/chemokine secretion in the serum or in 
stimulated spleen cells as well as specific cellular immune responses when compared with controls.
Conclusion—Immunization of mice with C5aR-P1 and C5aR-P2, either alone or in combination, was effective in reducing 
early atherosclerotic lesion development. The combined peptide is more potential than either epitope alone to reduce 
atherosclerotic lesion formation through the induction of a specific Treg cell response as well as blockage of monocyte 
differentiation into macrophages. (Arterioscler Thromb Vasc Biol. 2012;32:2358-2371.)
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Staphylococcus aureus,16 a 121-residue protein excreted by 
this bacterium, known to bind to human C5aR17 and therefore 
proposed as a new anti-inflammatory agent. In support of this 
claim, random mutagenesis of the C5aR-N-terminus in the 
region 19–29 was shown to be relatively highly conservative in 
the functional mutants.18 A study with the antiserum of C5aR 
(aa 9–29) indicated that this antiserum effectively blocks C5a-
mediated cell activation, which is because of interference with 
C5a binding to its receptor by interacting with the extracellular 
N-terminal region of the receptor.19 These data provide 
evidence to show that the N-terminal region of C5aR makes a 
productive physiological interaction with its ligand. Inhibition 
of complement C5aR using a peptidomimetic C5aR antagonist 
or a blocking anti-C5aR monoclonal antibody has recently 
been reported to limit neointimal formation after wire injury 
in atherosclerosis-prone ApoE−/− mice.20 However, the effect of 
antibodies induced by putative peptide epitopes of C5aR for 
binding of C5a on atherosclerotic lesion development has not 
been studied. Therefore, in the present study, we investigated 
the effects of immunization with 2 peptides derived from the 
N-terminus of C5aR on atherosclerotic lesion in the Ldlrtm1Her 
Apobtm2SgyJ mouse model.
Materials and Methods
Free and keyhole limpet hemocyanin (KLH)–conjugated C5aR-P (aa 
1–21 of C5aR), C5aR-P2 (aa 19–31 of C5aR), ApoB peptide, and 
human HSP60 peptide were synthesized by Severn Biotech Limited 
(Worcestershire, UK).
Peripheral Blood Mononuclear Cell Isolation 
From C57BL/6 Background Mice
Blood was diluted with PBS (1:4 dilution) and slowly layered onto 
preprepared Histopaque solution (1:1 v/v) (Sigma, Dorset, UK) in a 
centrifuge tube, followed by centrifugation (2000 rpm) at room tem-
perature for 20 minutes to collect mononuclear cells. The isolated 
peripheral blood mononuclear cells (PBMCs) were used for further 
flow cytometric analysis for their differentiation.
Animal Experiments
The experiments were approved by the Animal Welfare Committee of 
the University of Szeged and conformed with the Directive 2010/63/
EU of the European Parliament.
Ldlrtm1HerApobtm2SgyJ mice on a C57BL/6 background were used in 
our study, with a total of 4 groups, each comprising 8–10 females 
(5–6 weeks old; similar body weight; Table I in the online-only Data 
Supplement). The immunizing antigens KLH–C5aR-P1 and KLH–
C5aR-P2 were injected either alone at a dose of 20 μg per inocula-
tion or the 2 antigens (10 μg each) were combined. Each antigen was 
mixed with alum adjuvant. Control groups received KLH with alum. 
The repetitive immunization multiple sites strategy was adopted, and 
mice were killed at the end of week 12 after being fed a high-fat diet 
for 10 weeks (the diet was started at week 2 and was continued for 10 
weeks). For cross-reactive study, 3 groups of mice (6 per group) were 
immunized with C5aR-P1, C5aR-P2, and control KLH. Mice were 
fed normal chow for 5 weeks.
Antibody Response Measurements, Tissue 
Preparation, Size, and Composition 
of Atherosclerotic Lesions
Twelve weeks after the first immunization, heart segments with the 
aortic root were harvested and mounted in an optimal cutting temper-
ature component for immunohistochemical analyses and in paraffin 
for lesion measurement. Atherosclerosis in aortic roots was exam-
ined by Image-Pro Plus software, version 4.0 (Media Cybernetics, 
Bethesda, MD). The presence of collagen was determined by 
Sirius Red staining. Longitudinally opened descending aortas were 
evaluated for the extent of atherosclerosis after Oil Red O staining. 
Peptide-specific antibody titers were measured by ELISA per the 
manufacturer’s instructions.
Immunohistochemical and Morphometric Analyses 
and Quantitative Measurements of Atherosclerosis
Sections from optimal cutting temperature–embedded samples were 
stained with CD68-, CD11c-, CD4-, and forkhead box protein-3 
(Foxp3)-specific antibodies. Sections from paraffin-embedded tissues 
were stained with hematoxylin and eosin and elastin stain (Sigma) 
for histological examination and evaluated using an Olympus U-ULH 
Optical microscope (Olympus Optical Co. Ltd, Tokyo, Japan). The 
extent of atherosclerosis in the aortic roots and descending aortas was 
measured and analyzed quantitatively by using Image-Pro Plus soft-
ware version 4.0 (Media Cybernetics).
Measurement of Cytokines
Plasma concentrations of interleukin (IL)-10, transforming growth 
factor (TGF)-β, tumor necrosis factor (TNF)-α, and interferon 
(IFN)-γ were measured by ELISA per the manufacturer’s instructions 
(R&D Systems, Abingdon, UK). IL-10 and TNF-α concentrations in 
the lesions were quantified by immunohistochemical analyses (rat 
anti-mouse TNF-α and IL-10 were purchased from BioLegend, CA). 
Concentrations of ConA-induced IL-10, TGF-β, TNF-α, and IFN-γ 
in splenocyte cultures were also measured.
Antigen-Specific Regulatory Function Assays
For antigen-specific regulatory function, experiments were per-
formed as previously described,21,22 with some modification. In brief, 
CD4+CD25+ Treg cells were isolated from spleen CD4+ T cells of 
Ldlrtm1HerApobtm2SgyJ mice immunized subcutaneously with C5aR-P1-, 
C5aR-P2-, and C5aR-P1+P2.
T-effector cells, the CD4+CD25− cells, were isolated from CD4+ 
T cells (unbound to CD4+CD25+ cell beads, 99.5% of CD4+CD25− 
cells) from spleen of mice that had received oral immunization with 
C5aR-P1, C5aR-P2, and C5aR-P1+P2, respectively. CD4+CD25− 
cells (2×105) were cocultured with CD4+CD25+ cells (2×105), in the 
presence of 2×104 antigen-presenting cell (3000 rad irradiated sple-
nocytes) per well, and stimulated with 1 μmol/L C5aR peptides or 
with KLH control or without C5aR peptides. After 3 days of cul-
ture, cells were pulsed with 0.5 μCi of [3H]thymidine (Amersham, 
Buckinghamshire, UK) for the last 18 hours of culture and then har-
vested, and the incorporation of [3H]thymidine was determined using 
a liquid scintillation spectroscopy method (1205 Betaplate, Turku, 
Finland).
Real-Time Reverse Transcription–Polymerase  
Chain Reaction Analysis
Total RNA was extracted from the aorta arch using TRIzol reagent 
(Invitrogen, Carlsbad, CA). Reverse transcription–polymerase 
chain reaction was performed using a 2-step SYBR superscript 
reverse transcription–polymerase chain reaction kit (Invitrogen) 
and using an ABI PRISM 7500 sequence detection system (Applied 
Biosystems, CA) to analyze the expression of IL-10, TGF-β, TNF-α, 
and IFN-γ.
Fluorescence-Activated Cell Sorting Analysis
Cells (either PBMC or spleen cells) were processed for staining (30 
minutes at 4°C) using phycoerythrin-conjugated CD206 anti-mouse 
antibody (BioLegend, Cambridge, UK) and fluorescein isothiocya-
nate-F4/8 anti-mouse antibody (eBioscience, Hatfield, UK). Spleen 
cells from mice immunized with either C5aR peptides or KLH 






2360  Arterioscler Thromb Vasc Biol  October 2012
(control) were used for Treg measurement using a Treg detection kit 
(Miltenyi Biotec, Surrey, UK). Cells were analyzed with a Beckman-
Coulter FC-500 Analyzer (Beckman Coulter, High Wycombe, UK).
Statistical Analyses
Data are reported as mean±standard error of the mean (±SEM), 
unless otherwise indicated. Figures were plotted using GraphPad 
Prism 5.01 and Sigma plot 9.0. For atherosclerotic lesion size, data 
were compared and intergroup differences were conducted using 
1-way ANOVA for multiple comparisons and post hoc Bonferroni 
test. Other data were analyzed using Student t test (2-tailed analyses). 
Nonparametric distributions were analyzed using Mann-Whitney 
U test for pairwise comparisons and the Kruskal-Wallis test for mul-
tiple comparisons. Differences between groups were considered sig-
nificant at P<0.05.
Results
C5a and C5aR Are Involved in Lesion Sites
The results obtained from the tissues of mice immunized with 
C5aR peptides either alone or in combination showed that C5a 
or C5aR is expressed in the lesion sites of aorta sinus (Figure 
IA in the online-only Data Supplement) in mice immunized 
with different peptides or with KLH only as controls. Although 
both C5aR+ cells per mm2 lesion and the C5a percentage of 
area in the lesion showed somewhat similar profiles between 
the sampling groups and the control (Figure IB and IC in 
the online-only Data Supplement), most C5a were not colo-
calized with C5aR or the number of C5aR+C5a+ cells were 
decreased significantly in mice immunized with C5aR pep-
tides compared with those in KLH-immunized control mice 
showing almost all C5aR+ cells combined with C5a (Figure IA 
magnified, ID, and IE in the online-only Data Supplement). 
Interestingly, additional tissues of mice immunized with 
ApoB peptide, human HSP60 peptide either alone or in com-
bination showed that not only C5a or C5aR expressed in the 
lesions of aorta sinus but C5a colocalized with C5aR (Figure 
IF–IH in the online-only Data Supplement).
Peptide-Specific Antibody Measurement in 
the Sera of Immunized Mice, C5a Level in 
Plasma, and C5aR Levels in Lymph Nodes
After immunization of Ldlrtm1HerApobtm2SgyJ mice with KLH-
conjugated peptide antigens C5aR-P1 or C5aR-P2, or combi-
nation of C5aR-P1 and C5aR-P2, a peptide-induced specific 
immunoglobulin (Ig)G1 response was observed when 
compared with either KLH+alum or an alum-only control 
(Figure 1A). In addition, IgG2c antibody response was 
detected in the pooled serum of peptide-immunized mice at 
a low number of dilution times when compared with that in 
control (Figure 1B). However, the levels of IgG2c detected 
were much lower than those of IgG1 based on the optical 
densities measured in different dilutions of samples. Either 
IgG1 or IgG2c antibody response was significantly high 
compared with that of the controls. Furthermore, higher lev-
els of anti-oxLDL IgM and IgG were also detected in serum 
of mice immunized with either C5aR-P1 or C5aR-P2 and 
fed with normal chow when compared with those of native 
LDL (Figure IIA in the online-only Data Supplement). 
In contrast, some degree of anti-C5aR peptide antibodies 
was also detected in the pooled serum of mice immunized 
with ApoB peptide (Figure IIB in the online-only Data 
Figure 1. A, Levels of peptide-specific IgG1 antibodies in the sera of Ldlrtm1Her Apobtm2SgyJ mice at 2 and 12 weeks after the first immuni-
zation and in controls (alum alone and keyhole limpet hemocyanin [KLH]+Alum-immunized mice). The mean optical densities (ODs) ±SEMs 
from 6 mice (*P<0.05, **P<0.01, and ***P<0.001), compared with above 2 corresponding controls, that were considered statistically sig-
nificant are shown. Dilution ratio: 1:1250. B, Levels of peptide-specific IgG2c antibodies in the sera of Ldlrtm1Her Apobtm2SgyJ mice mice at 2 
and 12 weeks after the first immunization and in controls. The mean ODs from 6 mice (*P<0.05), compared with 2 corresponding controls, 
that were considered statistically significant are shown. Dilution ratio: 1:50.
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Supplement). The immunization with C5aR peptide did 
not alter C5a level (Figure IIC) and oxLDL level (Figure 
IID in the online-only Data Supplement) in the plasma and 
C5aR expression level in lymph nodes from C5aR peptide-
immunized mice, which showed similar levels to those 
from KLH-immunized mice (Figure IIE in the online-only 
Data Supplement).
Reduction of Atherosclerotic Lesion Size in 
Aortic Sinus and in Descending Aorta
Representative sections of aortic sinuses from experimen-
tal groups are shown in Figure 2A. Lesion size was signifi-
cantly smaller in mice immunized with either C5aR-P1 or 
C5aR-P2 (both P<0.001) compared with the KLH-alum–
immunized control group, either by regarding the mean 
lesion area (384 710±24 186 μm2) or the percentage of 
the total area occupied by lesion (45%±1.9%). Although 
there was a significant difference in lesion size between 
mice immunized with C5aR-P1 (221 415±5377 μm2) and 
C5aR-P2 (198 931±9196 μm2; P=0.035), there was no sig-
nificant difference between these 2 peptide antigens in terms 
of the percentage of the lesion versus total area in the aorta 
sinus (27.3%±1.4% for C5aR-P1 and 30.2%±0.81% for 
C5aR-P2; P=0.08) (Figure 2B and 2C). The smallest lesion 
area was observed in mice immunized with the combina-
tion of the 2 peptides (171 480±9276 μm2 based on lesion 
area; P<0.07 to P<0.001) when compared with the single 
peptide–immunized mice. With respect to the percentage of 
the lesion area versus total area in the aorta sinus (Figure 
2C), the difference was significant only between the com-
bined peptide and the C5aR-P2, showing 25.3%±1.2% 
versus 30.2%±0.81% (P<0.001). Reduction in lesion size, 
expressed as a percentage of the decrease in the lesion size in 
the aortic sinus of peptide-immunized mice calculated with 
respect to the mean lesion size in the KLH-alum-immunized 
control mice, was significant (P<0.001), showing a 39.3% 
reduction (27.3% versus 45%) after immunization with 
C5aR-P1 and a 32.7% reduction (30.28% versus 45%) with 
C5aR-P2 (Figure 2C). Mice immunized with the combined 
peptides showed a significant reduction (25.3% versus 45%) 
in lesion size (43.7%; P<0.001), which was also significant 
when compared with the mice immunized with C5aR-P2 
(P<0.001) (Figure 2C).
We also examined the impact of treatment with C5aR 
peptides on the collagen in these lesions. The reduction 
of atherosclerosis in mice treated with these peptides was 
associated with an increase in collagen content: 2-fold 
(46 061±10 138 μm2 versus 23 536±3890 μm2; P=0.018) for 
C5aR-P1, 1.8-fold (42 859±4936 μm2 versus 23 536±3890 
μm2; P=0.016) for C5aR-P2, and 3-fold (71 075±13 816 μm2 
versus 23 536±3890 μm2; P=0.001) for the combined peptides 
(Figure 2D and 2E). Mice immunized with the combined 
peptides showed a significant collagen increase compared 
with mice immunized with the peptides alone (P=0.033, and 
P=0.006, respectively).
Longitudinally opened descending aortas were stained en 
face with Oil Red O, and positively stained plaque areas were 
measured. Representative en face stained descending aortas 
from experimental groups are shown in Figure 2F. Lesion 
size was significantly smaller in mice immunized with a 
single peptide (C5aR-P1: 4.7%±0.2%, P=0.015; C5aR-P2: 
6.1%±0.2%, P=0.045) or with the combined peptides (C5aR-
P1+P2: 2.7%±0.4%, P=0.008) compared with that in control 
mice (9.9%±1.5%) (Figure 2G). Reduction in lesion size 
was expressed as a percentage of the decrease in the lesion 
size versus total size in the descending aorta of peptide-
immunized mice compared with that in control mice (set as 
0% of reduction), showing 52.5% after immunization with 
C5aR-P1, 38.4% with C5aR-P2, and 72.8% with the com-
bined peptide (Figure 2G). The increased reduction in lesion 
size in the descending aorta from the mice immunized with 
the combined peptide was significant compared with that in 
mice immunized with either C5aR-P1 (P<0.01) or C5aR-P2 
(P<0.01).
Inflammatory Cell and Foxp3-Expressing CD4+  
Cell Content in Lesions, Foxp3 mRNA 
Expression in Lymph Nodes
The percentage of macrophage-occupied area in the lesions 
decreased significantly. The reduction was 68.7% (10.6% 
versus 33.9%; P<0.001) in mice immunized with C5aR-P1, 
63.7% (12.3% versus 33.9%; P<0.001) in mice immunized 
with C5aR-P2, and 82.1% (6.1% versus 33.9%; P<0.001) in 
mice immunized with C5aR-P1+C5aR-P2 (Figure 3A and 
3B). Total macrophage-occupied area in lesions in control 
mice (33.9%) was set at 100% (0% reduction).
The percentage of the CD11c+-stained area in the lesion 
showed a significant reduction in mice, of 74.1% (6.9% 
versus 26.6%; P<0.001) in mice immunized with C5aR-P1, 
70.0% (8.0% versus 26.6%; P<0.001) in mice immunized 
with C5aR-P2, and 81.6% (4.9% versus 26.6%; P<0.001) 
in mice immunized with C5aR-P1+C5aR-P2 compared 
with the CD11c+ content of the lesions in control group 
(Figure 3C).
The proportion of CD4+ cells expressing Foxp3 in the 
lesions was ≈3- to 4-fold higher in mice immunized with 
C5aR-P1 (2.8%; P<0.001), C5aR-P2 (2.6%; P<0.05), or 
C5aR-P1+C5aR-P2 (3.7%; P<0.001) compared with 0.9% in 
control mice (Figure 3D and 3E). In addition, higher levels 
of Foxp3+ cells were found for the combined peptides versus 
those either in mice immunized with C5aR-P1 (P<0.05) 
or C5aR-P2 (P<0.01). The flow cytometric analysis of 
spleen cells showed significantly increased expression of 
CD4+CD25+Foxp3+ in mice immunized with 2 peptides either 
alone or in combination compared with the KLH control 
(Figure 3F and 3G). Similar to the observation in the lesions, 
higher expression of Foxp3+ was also found for the combined 
peptides versus those in either C5aR-P1 (P<0.05) or C5aR-P2 
(P<0.05).
Consistently, mRNA expression of Foxp3 in lymph nodes 
showed 1.8-fold, 1.7-fold, and 2.2-fold increases (Figure IIIA 
in the online-only Data Supplement) in mice immunized with 
C5aR-P1, C5aR-P2, and C5aR-P1+P2, respectively, when 
compared with controls.






2362  Arterioscler Thromb Vasc Biol  October 2012
Figure 2. Detection and quantitation of 
lesion areas in the aorta and descend-
ing aorta of Ldlrtm1HerApobtm2SgyJ mice fed 
a high-fat diet after immunization with 
C5aR peptides vs controls (keyhole lim-
pet hemocyanin [KLH]). A, Representative 
photomicrograph of lesions observed in 
atherosclerotic aortas as analyzed with 
elastin/van Gieson staining. Scale bar: 
250 μm. B, Lesion area in μm2. C, Per-
centage of luminal surface occupied by 
lesions in the aortic sinus (percentage of 
ratio of lesion areas in μm2 vs. total areas 
in μm2) (n=18 sections, 3 sections per 
mouse). D and E, Representative pho-
tomicrographs and quantitative analysis 
of collagen (Sirius Red coloration under 
polarized light) in atherosclerotic aortas in 
individual mice (n=6). F, Representative 
stained en face descending aorta from 
mice. G, Percentage of lesion-occupied 
area vs total area of descending aortas 
in individual mice (n=6) of the different 
experimental groups. The mean lesion 
size and the difference in lesion size 
between the experimental groups are 
shown.
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Figure 3. (Continued)
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Expression of Anti- and Proinflammatory Cytokines 
in Lesion Sites, mRNA Expression of Cytokine in 
Aorta Arch, Cytokine Concentrations in Plasma 
and in Supernatants of Stimulated Splenocytes
Anti-inflammatory cytokine IL-10 expression, as detected by 
immunohistochemistry, in the aortic lesions of mice immu-
nized with the peptides is shown in Figure 4A. The proportion 
of CD4+ cells expressing IL-10 per mm2 lesion was ≈1.5- 
fold higher in mice immunized with the combined peptides 
compared with peptides used alone (3.3%±0.4% versus 
4.5%±0.4% for C5aR-P1; 3.2%±0.4% for C5aR-P2; P<0.05). 
The higher IL-10 content was also found for peptides used 
alone versus those  in controls (0.9%±0.1%) (Figure 4B).
Immunohistochemical analyses showed significantly 
smaller TNF-α occupied areas in the lesions of mice immu-
nized with the combination peptides compared with peptides 
used alone (6.7%±0.47% for C5aR-P1+C5aR-P2 versus 
17.2%±1.0% for C5aR-P1 and 14.0%±1.5% for C5aR-P2). 
In addition, a reduction in the TNF-α–occupied lesion areas 
was observed in mice receiving peptides alone compared with 
controls (44.5%±2.4%) (Figure 4C and 4D).
Consistently, mRNA expression of cytokines in the aorta 
arch showed 3.8-fold, 1.3-fold, and 5.1-fold increases in 
the expression of IL-10 (Figure IIIB and IIIF in the online-
only Data Supplement) for C5aR-P1, C5aR-P2, and C5aR-
P1+P2, respectively, whereas 6.6-fold, 2.3-fold, and 16.3-fold 
increases in the expression of TGF−β (Figure IIIC and IIIF 
in the online-only Data Supplement) for C5aR-P1, C5aR-P2, 
and C5aR-P1+P2, respectively. By contrast, 2.6-fold, 4.5-
fold, and 4.7-fold decreases were observed in the expres-
sion of TNF-α Figure IIID and IIIF in the online-only Data 
Supplement), and 1.1-fold, 1.4-fold, and 3.0-fold decreases in 
the expression of IFN-γ (Figure IIIE and IIIF in the online-
only Data Supplement) for C5aR-P1, C5aR-P2, and C5aR-
P1+P2, respectively. These results were consistent with 
cytokine levels measured in the plasma and in the supernatants 
of splenocytes.
Plasma concentrations of IL-10 (P<0.05) and TGF-β 
(P<0.01) were increased significantly in mice immunized 
with either the C5aR-P1 or C5aR-P2 peptide antigens com-
pared with controls (Figure 4E and 4F); even higher concen-
trations were observed in mice immunized with the combined 
peptides than with either alone. The difference is significant 
for IL-10 (P<0.05; C5aR-P1+C5aR-P2 versus C5aR-P1) 
and TGF-β (P<0.05; C5aR-P1+C5aR-P2 versus either 
C5aR-P1 or C5aR-P2). In contrast, the plasma concentration 
Figure 3. Assessment of the presence of inflammation-associated cells in lesions of Ldlrtm1HerApobtm2SgyJ mice fed a high-fat diet after 
immunization with C5aR-P1, C5aR-P2, or C5aR-P1+C5aR-P2. A, Representative photomicrographs showing immunohistochemical stain-
ing of CD68 (green) and CD11c (red) markers in the aorta sections of different experiment groups. B, Percentage of positively stained 
lesion areas vs total lesion area for CD68. C, Percentage of positively stained lesion areas vs total lesion area for CD11c. D, Photomi-
crographs showing immunohistochemical staining of CD4+ T cells (green) and Foxp3+ Treg cells (red). E, Assessment of Treg cells as 
percentage of Foxp3+ areas colocalized with CD4+ area shown in yellow (n=18 sections). F, Representative flow cytometric plots for 
CD4+CD25+Foxp3+ (Treg) cell population in spleen cells. Spleen cells from mice immunized with either C5aR peptides or keyhole limpet 
hemocyanin (KLH) (control) were performed using a Treg detection kit (Miltenyi Biotec, Surrey, UK) according to manufacturer’s proto-
cols. G, Bar chart presentation of flow cytometric analysis. Data represent mean±SEM from 3 independent samples. *P<0.05, **P<0.01, 
and ***P<0.001. Foxp3 indicates forkhead box protein-3.
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Figure 4. (Continued)
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Figure 4. Assessment of cytokine concentrations in lesion sites, plasma, and supernatant of spleen cells stimulated by either ConA or 
C5aR peptides. A, Representative photomicrographs showing dual-immunohistochemical staining of aorta section of mice from different 
experimental groups for interleukin (IL)-10-producing T cells, IL-10 (red), and CD4 (green). B, Percentage of CD4+ cell expressing IL-10 per 
mm2 lesion. The figures are based on values from all animals using the mean of 3 sections from each animal (n=6 mice). C, Representative 
photomicrographs for tumor necrosis factor (TNF)-α-positive area (green) in aorta sections from mice of different experimental groups. D, 
Percentage of TNF-α-positive area of the lesions vs total lesion area (n=18 sections). Magnification is same as that in (4A).  
E–H, Concentrations of cytokines IL-10, transforming growth factor (TGF)-β, TNF-α, and interferon (IFN)-γ in plasma from Ldlrtm1HerApobtm2SgyJ 
mice fed a high-fat diet after immunization with peptide antigens or with control keyhole limpet hemocyanin (KLH). I–L, Concentrations 
of cytokines for IL-10, TGF-β, TNF-α, and IFN-γ in the supernatant of splenocytes stimulated with different concentrations of ConA from 
Ldlrtm1HerApobtm2SgyJ mice fed a high-fat diet after immunization with peptide antigens or with control KLH. M and N, Concentration of 
cytokine for IL-10 and IFN-γ in the supernatant of splenocytes stimulated with C5aR-P1+C5aR-P2 (10 μg/mL for each peptide) from  
Ldlrtm1HerApobtm2SgyJ mice fed a high-fat diet after immunization with C5aR-P1+C5aR-P2 (5 analyses±SEM and differences between  
experimental groups are shown). Data represent mean±SEM from 6 mice of each group. *P<0.05, **P<0.01, and ***P<0.001.
of the atherogenic cytokine TNF-α was reduced (P<0.05) 
by immunization with the 2 peptide antigens individu-
ally compared with that in controls, whereas a significant 
reduction of TNF-α was observed in mice immunized with 
C5aR-P1+C5aR-P2 versus controls (P<0.001) (Figure 4G). 
A significant difference was also shown in mice immunized 
with the peptides given in combination versus individually. 
A trend similar to that observed for the plasma concentra-
tions of TNF-α was found with respect to the plasma levels of 
IFN-γ after immunization with the peptides used either alone 
or in combination (Figure 4H). Although no statistically sig-
nificant difference was found between mice immunized with 
C5aR-P2 and C5aR-P1+C5aR-P2 (P=0.156) in plasma levels 
of IFN-γ, a significant difference was found between mice 
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immunized with C5aR-P1 and C5aR-P1+C5aR-P2 (P=0.039) 
(Figure 4H).
Supernatants of splenocytes from mice immunized with 
these peptide antigens used either alone or in combination 
showed significantly increased secretions of IL-10 (Figure 
4I) and TGF-β (Figure 4J), when stimulated with 10 or 100 
μg/mL of ConA (P<0.05–0.001). The secretion of IL-10 
in C5aR-P1+C5aR-P2-immunized mice was significantly 
higher than for C5aR-P2 used alone. In contrast, the 
decreased secretion of TNF-α (Figure 4K) and IFN-γ 
(Figure 4L) was found in supernatants of splenocytes in 
mice immunized with these 2 peptides used either alone or in 
combination (P<0.01–0.001) when compared with controls. 
Again, a significantly greater decrease in the secretion of 
IFN-γ was observed in mice immunized with peptides used 
in combination versus alone (Figure 4K; P<0.05–0.01), but 
this was not the case with respect to the secretion of TNF-α, 
which showed no difference between peptides used either 
alone or in combination. IL-10 and IFN-γ produced by 
splenocytes from the mice immunized with a combination 
of C5aR peptides after 48-hour incubation with the same 
peptides were measured as well. Incubation with both 
C5aR-P1 and -P2 peptides resulted in a significantly larger 
production of IL-10 (17±3.0 versus 6±1.5; P=0.027) and a 
significantly decreased production of IFN-γ (23±2.6 versus 
18.6±1.5; P=0.023) when compared with the spleen cells 
cultured without C5aR peptides (Figure 4M and 4N; the 
ConA used as a positive control).
Antigen-Specific Regulation Function
CD4+ T cells from the spleens of mice immunized with 
the peptide antigens were incubated with the correspond-
ing immunizing antigens at 0–10 μmol/L, and a dose-
dependent significant increase in proliferative response 
was shown between 0.1 and 1 μmol/L of peptide concen-
trations (Figure IV in the online-only Data Supplement). 
CD4+ T-cell proliferative responses were observed from 
antigen-immunized mice incubated with the correspond-
ing immunizing antigen and the response was specific 
(Figures IVA–IVC in the online-only Data Supplement) 
compared with those incubated with KLH control in which 
the responses were smaller and nonspecific (Figure IVD 
in the online-only Data Supplement). Because the prolif-
erative response can only be used as a general indicator 
of T-cell reactivity, we further assessed whether functional 
Treg cells were induced by immunization. We cocultured 
antigen-specific (for the C5aR epitope) Treg cells with 
CD4+ effector T cells (CD4+CD25− T cells). T-effector-cell 
proliferation was suppressed in a dose-dependent manner 
in the presence of Treg cells from C5aR peptide–immu-
nized mice either alone or in combination (Figure 5A–5C). 
The differences were significant when adding equal or half 
the amount of Tregs into the effector cells (1:1 and 2:1) 
(P<0.01), with the exception of 4:1 in mice immunized 
with both peptides simultaneously (P<0.05). No such sup-
pression was observed from KLH-immunized control mice 
(Figure 5D). In addition, Treg cells from KLH-control mice 
did not suppress T-effector-cell proliferation in the pres-
ence of C5aR peptides, further supporting the antigen spec-
ificity of the Treg-cell function.
Evaluation of Monocyte Differentiation Into 
Macrophages in PBMC From C57BL/6 Background 
Naïve Mice and Detection of Spleen Cells From 
Peptide-Immunized or KLH-Immunized Mice
Mouse (C57BL/6) PBMCs were stimulated with granulo-
cyte-macrophage colony-stimulating factor in the presence 
or absence of C5a or C5a antisera/C5aR peptide antisera. 
Figure 5. Assessment of antigen-specific 
regulatory function. T-effector cells, the 
CD4+CD25− cells, were isolated from 
CD4+ T cells (unbound to CD4+CD25+ cell 
beads, 99.5% of CD4+CD25− cells) from 
spleen of mice that had received oral 
immunization with C5aR-P1, C5aR-P2, 
and C5aR-P1+P2, respectively. Prolifera-
tion of effector cells alone is indicated in 
the leftmost bar of each group. Addition 
of isolated CD4+CD25+ Treg cells from 
animals immunized (A) with C5aR-P1, (B) 
with C5aR-P2, (C) with C5aR-P1+ P2, and 
(D) with keyhole limpet hemocyanin (KLH) 
control is indicated at different ratios to 
affect cells. Data are expressed as mean 
of 6 analyses±SEM. Differences between 
groups are shown; *P<0.05 **P<0.01, and 
***P<0.001.
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After 3 days, the expression of cell-surface markers CD206 
(macrophage marker) and F4/80 (monocyte/macrophage 
marker) was assessed. C5a induced monocyte differentiation 
into macrophages (based on the cell number changes) when 
compared with fresh cells or nonstimulated cells or stimu-
lated with dendroaspin (unrelated protein), in which case 
little differentiation was observed. However, PBMC differ-
entiation induced by C5a was abolished by preincubation of 
the cells with the antiserum of either C5a or C5aR (P<0.001; 
Figure 6A and 6B). Concordantly, fewer macrophages were 
observed in the spleens of mice immunized with C5aR peptides 
compared with mice immunized with KLH (control) as shown 
by the considerable decrease in CD206 (macrophage marker) 
expression on splenocytes of C5aR peptide-immunized 
mice when compared with that from control mice (P<0.001; 
Figure 6C and 6D).
Discussion
Previous studies have reported that atheroprotective effects 
can be achieved by subcutaneous and nasal immunization of 
autoantigen such as human ApoB-100 and its peptide, which 
was involved in antigen-specific Treg cells in mediating 
the autoantigen-induced immunity toward atheroprotective 
effects.21–23 In this study, we investigated whether subcutane-
ously immunizing Ldlrtm1HerApobtm2SgyJ mice with 2 peptides 
derived from nonautoantigen C5aR had an effect on athero-
sclerotic lesions when the mice were fed a high-fat diet. These 
2 peptides, located in the N-terminal extracellular domain 
Figure 6. Measurement of monocyte differentiation into macrophages by flow cytometry. A, Peripheral blood mononuclear cells (PBMCs) 
isolated from C57/B6 background mice (same background as Ldlrtm1HerApobtm2SgyJ mice) were cultured for 3 days and their differentiations 
determined by assessing expression of CD206 and F4/80 using flow cytometry. Histograms show expressions in fresh cells (control), 
unstimulated cells (control), dendroaspin-stimulated (10 ng/mL) cells, C5a-stimulated (10 ng/mL) cells, C5a/C5aR antiserum (C5a stimu-
lation after C5aR antiserum-pretreatment) treated cells, C5a/C5a antiserum (C5a stimulation after C5a-antiserum pretreatment) treated 
cells, and granulocyte-macrophage colony-stimulating factor-(GM-CSF) stimulated cells (shown in red) compared with that of isotype 
control (shown in black). Numbers show mean fluorescence intensity (MFI). B, CD206 and F4/80 expression in peripheral blood mono-
nuclear cells (PBMCs) of C57/B6 mice presented as MFI. C, Spleen cells from C5aR-peptide-immunized mice were analyzed using a flow 
cytometer, and expression of CD206 was detected. Histogram presentations for CD206 expression by spleen cells of mice in different 
groups and numbers showing MFI. D, MFI values for CD206 expression by splenocytes. Data represent mean±SEM from 3 independent 
samples. ***P<0.001.
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of the receptor, were selected because they are thought to 
interact with C5a.14 Their combination showed a synergistic 
effect on atherosclerotic lesion reduction, indicating that the 
N-terminus of C5aR aa sequence (1–35) is immunogenic and 
is involved in reduction of lesion through immunization in this 
mouse model.
We first measured whether C5a or C5aR is present in the 
atherosclerotic lesions. Both were found to be involved at the 
lesion sites, reaching approximately similar levels in experi-
mental groups with reduced lesion development in response to 
immunization with C5aR peptides, alone or in combination, as 
well as in control groups. These findings suggest that C5a and 
C5aR are associated with lesion development. Surprisingly, 
we found that immunization with C5aR peptides obviously 
reduced lesion development despite that the peptides had no 
effect on the expression of both C5a and C5aR, suggesting 
that immunization with C5aR peptides may affect the function 
of inflammatory cells rather than the expression of C5aR and 
C5a. It is interesting to note by our observation that the C5a 
cannot effectively bind to C5aR expressed on inflammatory 
cells in lesions in mice immunized with C5aR peptides, indi-
cating a possible mechanism that C5aR antibody produced by 
immunization with C5aR peptides may occupy the site which 
was for C5a binding on the surface of C5aR+ cells in lesions, 
therefore blocking C5a binding to C5aR.
We then characterized the effect of immunization with 2 
C5aR peptides, either alone or in combination, on the 
development of atherosclerotic lesions. The results from 
our study show that immunization induced an IgG1 isotype 
specific to each antigen peptide, alone or in combination, 
when an individual peptide was used as an ELISA antigen. 
However, these peptides could induce only a weak peptide-
specific IgG2c isotype response based on the observed optical 
density values, suggesting that vaccination with these peptides 
acts predominantly through the Th2 pathway. Interestingly, 
the anti-oxLDL and anti-native LDL IgG and IgM were 
detected in mice immunized with 2 peptides and fed normal 
chow, suggesting that cross-reactivity exists in C5aR-peptide-
immunized mice. The reason we used normal chow was in 
view of the fact that a high-fat diet may affect the levels of 
anti-oxLDL and anti-native LDL IgG and IgM.24 Indeed, 
several locations in the ApoB (a protein of oxLDL) sequence 
have a high percentage of homology to the sequence of either 
C5aR-P1 or C5aR-P2, but this is not the case for ApoB 
peptide (aa 688–707), which shows little homology to C5aR 
peptides using the computer-based software SIM-Alignment 
Tool for protein or peptide sequences (http://web.expasy.org/
tools/sim) (data not shown). In this regard, the former could 
explain why sequence homology dictates cross-reaction; the 
latter may be due to antigenic surfaces rather than sequence 
homology that controls cross-reactivity.25 Although the precise 
role of anti-oxLDL IgG in atherosclerosis remains unclear, 
anti-oxLDL-IgM induced by C5aR peptide immunization 
presumably plays an atheroprotective role in this regard; 
Cesena et al26 recently reported that polyclonal IgM reduces 
advanced spontaneous aortic atherosclerosis as well as injury-
induced accelerated carotid atherosclerosis in an ApoE−/− 
mouse model study. Interestingly, in the present study, C5a 
levels in the plasma and C5aR expression in the lymph nodes 
in C5aR-peptide-immunized mice remained the same, but the 
functions (macrophage activation and inflammatory cytokine 
production) requiring receptor ligand interaction were impaired 
after immunization of C5aR peptides.
The peptide-induced immune response was associated with 
an antiatherogenic effect, detected as a significant reduction 
in the size of the atheromatous lesion. Although the type of 
antibody response against an antigen coexisting with expanded 
Treg cells specific to the same antigen remains unclear, our 
data clearly show predominance of a Th2 type IgG1 response, 
which cross-reacts with oxLDL. The induced antibodies 
cross-reacted with ApoB, and this self-antigen ApoB-specific 
humoral immune response may be associated with a cellular 
response.9
It has previously been reported that decreased collagen con-
tent and increased concentrations of macrophages, activated 
CD4+ T cells, and dendritic cells (markers of early lesion for-
mation) occur during lesion formation.21,27–29 In that perspective, 
it is interesting that our data demonstrate that immunization 
influences collagen content in lesions and cellular infiltration 
into atherosclerotic lesions because relatively increased colla-
gen content, low numbers of macrophages, CD4+ T cells, and 
CD11c+ cells, and high numbers of Treg cells were observed in 
lesions in mice immunized with these peptides.
The additive effect of immunization with a combination of 
peptides to that achieved by immunization with each alone 
suggests that the binding site on the C5aR N-terminus overlaps 
with the 2 peptides, although it cannot be excluded that certain 
residues at the N-terminus of C5aR-P1 or the C-terminus of 
C5aR-P2 are not involved in reduction of lesion.
TNF-α and IFN-γ are crucially involved in the progression 
of atherosclerosis.30,31 On the basis of the cytokine profiles 
from either plasma or spleen cells in immunized mice, TNF-α 
and IFN-γ secretion may well be linked to the ability of the 
immune animals to release these cytokines from preprimed 
cells, leading to a decrease in the need to synthesize significant 
amounts of new TNF-α and IFN-γ. Our results show that 
vaccination with peptides promoted a major shift away from 
proinflammatory cytokines (ie, TNF-α and IFN-γ) toward anti-
inflammatory cytokines (IL-10 and TGF-β), which is evident 
not only in the plaque but also systemically. These results 
were also consistent with the up-regulating anti-inflammatory 
cytokine mRNA expression and down-regulating atherogenic 
cytokine mRNA expression. Although these results strongly 
suggest that an anti-inflammatory response is responsible for 
the observed reduction in plaque size, they do not discriminate 
the reductions attributed to either of the anti-inflammatory 
cytokines, as both IL-10 and TGF-β have been implicated in 
playing a role in atherosclerosis.32,33 A strategy using TGF-β 
knockout mice is planned in a future study to delineate the 
relative contributions of these 2 cytokines.
The CD4+ T-cell-specific proliferative response in the C5aR 
peptide-immunized mice indicated that a cellular immune 
response was involved in the reduction of atherosclerotic 
lesion size. The mechanism of this reduction may be due to 
C5aR peptide immunization blocking monocyte differentia-
tion into macrophages through the regulation of the C5aR/C5a 






2370  Arterioscler Thromb Vasc Biol  October 2012
interaction. Our findings show that using C5aR peptides to 
immunize mice will not affect C5aR expression and C5a 
release from cells but will affect the ability of inflammatory 
cells to secrete cytokines. One possible explanation could be 
that C5a could not exert its cellular reaction in C5aR-peptide-
immunized mice because C5aR seemed to lose its binding site 
to C5a. In addition, the atheroprotective effect paralleled an 
induction of CD4+CD25+ Treg suppression of C5aR-peptide-
specific effector T cells in vitro. Furthermore, our findings 
also show that Foxp3 seems to be highly expressed in aortas, 
splenocytes, and lymph nodes in mice immunized with C5aR 
peptides as Foxp3+ Treg cells are known to be atheroprotec-
tive.34 Although CD4+CD25− T cells also expressed Foxp3, 
or regain CD25 expression and act as regulatory cells,35 the 
degree of expression of Foxp3 was significantly less than that 
of CD4+CD25+ T cells, at least under the conditions described 
in our study, there was no evidence of a regulatory effect for 
purified CD4+CD25− cells.
Antigen-specific regulation function has been demon-
strated in intranasal immunization22 and subcutaneous 
immunization21,23 using the same epitope within ApoB-100. 
In agreement with our present findings, it appears that 
modulation in atherosclerosis-related autoimmunity by 
antigen-specific activation of Tregs represents a novel 
approach for the treatment of atherosclerosis. We also found 
that both C5a protein and C5aR are expressed in the lesion sites 
of aorta sinus in mice immunized with ApoB peptide or with 
a human heat shock protein 60 peptide, as well as with KLH 
control (Figure IF–IH in the online-only Data Supplement). 
Interestingly, colocalization of C5a with C5aR was shown 
at similar levels in the lesions of peptide-immunized and 
control mice (Figure IH in the online-only Data Supplement), 
suggesting that C5a and C5aR are associated with lesion 
development through a different mechanism from that 
associated with ApoB peptide or human heat shock protein 
60 peptide; therefore, immunization with the C5aR peptides 
reducing lesion size may be through a different pathway 
from that associated with immunization of ApoB or human 
heat shock protein 60 peptides. In this regard, C5aR peptide 
immunization implies that C5aR could serve as a useful target 
for the development of antiatherosclerotic agents particularly 
as the binding of C5a to C5aR is known to exert a range of 
biological effects, which may contribute to the formation 
of atherosclerosis. In agreement with the findings of the 
present study, another recently reported study of the effect 
of treatment of ApoE−/− mice with a CD88 (C5aR) antagonist 
(PMX53) showed a reduction in lesion size, substantiating a 
role for C5a in atherosclerosis.36 In addition, C5a and C5aR 
are expressed in human coronary plaque.37,38 Conversely, a 
study using C5/ApoE double-knockout mice fed a high-fat 
diet failed to demonstrate any difference between C5-deficient 
and C5-sufficient animals, suggesting little contribution to 
atherosclerosis by C5a39; these results could be explained 
as attributable to the increased inflammatory environment 
overriding any effects of C5 deficiency as using a high-fat 
diet is associated with increased release of inflammatory 
cytokines and chemokines,40,41 and of oxLDL antibody.23
Our data show that antibodies produced by immunization 
of C5aR peptides could prevent monocyte differentiation 
into macrophages, an important step in disease progression. 
Therefore, it is feasible to propose that the mechanism respon-
sible for the ability of C5aR-derived peptide antibodies to 
reduce atherosclerotic lesions could be due to both a humoral 
response as well as a cell-mediated regulatory response to the 
antigen; immunization-induced specific Treg cells dampen the 
atherogenic ApoB-specific cellular immune response; binding 
of C5aR peptide-induced antibodies to oxLDL could poten-
tially decrease proinflammatory activities, thereby reducing 
atherosclerosis.
The precise role of the C5a/C5aR interaction in athero-
sclerosis remains, however, the subject of continuing inves-
tigation. Our present study reported for the first time that 
C5aR N-terminal peptide immunization is able to modulate 
oxLDL-specific immunity (cross-reaction) and highlights 
that the effect of immunization of these C5aR peptide epi-
topes on the reduction of atherosclerotic lesion formation 
through the mechanisms of inducing a specific Treg-cell 
response as well as blockage of monocyte differentiation into 
macrophages.
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Immunization with a combination of 2 peptides derived from the C5a receptor 
significantly reduces early atherosclerotic lesion in Ldlrtm1Her Apobtm2SgyJ mice 
 
Xinjie Lu*, Min Xia, Valeria Endresz, Ildiko Faludi, Lakshmi Mundkur,
 











J mice (The Jackson Laboratory, Maine, USA) were used, with a total of 5 
groups (3 sample groups and 2 control groups), each comprising 8–10 female mice (5–6-weeks’ old) 
with similar body weights. For subcutaneously immunization with the antigens, the repetitive 
immunization multiple sites strategy (RIMMS) was adopted [1,2]. Mice were inoculated 5 times at 2–3-
day intervals. At each immunization mice received 20 g of KLH-conjugated peptide mixed with 50 l 
Alum adjuvant (Aluminum hydroxide gel, Sigma). Group 1 received KLH–C5aR-P1 (peptide 1), group 
2 received KLH–C5aR-P2 (peptide 2), group 3 received a combination of KLH–C5aR-P1 and KLH-
C5aR-P2 (10 g each), group 4 were injected with a combination of KLH and Alum, and group 5 were 
injected with Alum only and for the purpose of observation of immune response only. According to a 
modified RIMMS protocol, this mix was subcutaneously injected into 8 sites (30 L for each site) [1,2]. 
For the study of cross-reaction with oxLDL and native LDL, 3 additional groups of mice (6 per group) 
were immunized with C5aR-P1, C5aR-P2, and control KLH. Mice were fed with normal chow for 5 
weeks. For isolation of T-effector cells, additional groups of mice (8 per group) (KLH only, C5aR-P1, 
C5aR-P2, and C5aR-P1+C5aR-P2) were administered orally with 20 µg of antigen on days 0, 2, 5, 7 
and 9 (5 times) using a gavaging needle. Mice were given 2 mg of soybean trypsin inhibitor before 
oral feeding. Peptides were synthesized and conjugated to KLH by Severn Biotech Ltd, UK. From the 
third week of the experiment the mice were fed a high-fat diet (a modified recipe of TD96121 and 
TD88137 with 21% anhydrous milk fat and 1.25% cholesterol (Altromin Spezialfutter GmbH & Co, 
Germany) for 10 weeks.  
 
 2 
Antibody Response Measurement  
Blood samples were collected in heparinized capillaries by retro-orbital bleeding at week 2, and 12 
weeks after the first injection of the antigens to test antibody production. The free C5aR-P1 and 
C5aR-P2 containing an N-terminal cysteine (synthesized by Severn Biotech Ltd, Worcestershire, UK) 
were used in ELISA as antigens. Maleimide-activated 96-well plates (Pierce, Thermo Fisher Scientific 
Inc., Hampshire, UK) were coated with these peptides individually and peptide-specific IgG1 and 
IgG2c were detected in the plasma of immunized mice according to the manufacturer’s instructions. 
1:1250 and 1:6250 dilutions of plasma samples were prepared before assaying for peptide-specific 
IgG1 and 1:50 and 1:250 dilutions were used for IgG2c detection. Horseradish peroxidase (HRP)-
conjugated anti-mouse IgG1 (Biosource, San Joe, CA, USA) and HRP-conjugated anti-mouse IgG2c 
(Abcam, Cambridge, UK) were used as the secondary antibodies. 
 
For ELISA analysis of cross-reaction with oxLDL/LDL, microtiter plates were coated with 15 g/mL of 
LDL or oxLDL in a coating buffer with 100 mM NaHCO3 and 1 mg/mL Na EDTA. Plates were then 
washed thoroughly with PBS with 0.05% Tween-20 and incubated with PBS with 5% BSA for 30 min 
at room temperature to prevent nonspecific binding. Mouse sera were incubated for 1 h at 37 C in 
duplicate wells, using a serum dilution of 1/100 in PBS Tween. After washing, HRP-conjugated 
antibodies to mouse IgM/IgG were used as the secondary antibodies. Copper oxidation of LDL was 
performed by incubation of LDL (1 mg of protein/mL in EDTA-free PBS) with copper sulfate (10 mM) 
for 24 h at 37 C. Oxidation was terminated with 10 mM EDTA and dialysis against 150 mM NaCl and 
0.01% EDTA to remove CuSO4. We also measured cross reaction using previously stored serum from 
ApoB peptide (aa 688-707)-immunized mice [2] against C5aR peptides as antigens. For the 
measurement of C5a concentration in plasma, a mouse C5a (mC5a) ELISA kit (IBL International 
GmbH, Hamburg, Germany) was used according to the manufacturer’s instructions. For the 
measurement of oxLDL concentration in plasma, a mouse oxLDL ELISA kit (USCN, life Science Inc, 
Wuhan, China) was used according to the manufacturer’s instructions.  
 
Tissue Preparation  




J mice as 
follows: 12 weeks after the first immunization, tissues were harvested and mounted in optimal cutting 
 3 
temperature (OCT) for immunohistochemical analyses or paraffin for lesion measurement. The OCT-
embedded samples were frozen in the mounting medium (OCT compound, Tissue-Tek, Sakura 
Finetek, Europe) from which 5- m thick sequential sections were taken using a Reichert-Jung Cryocut 
1800 (Leica). The paraffin-embedded sections (5- m thick) were prepared using a Leica Jung 
RM2055 microtome.  
 
Morphometric Analyses, Quantitative Measurements of Atherosclerosis, and Composition of 
Atherosclerotic Lesion 
Slides with paraffin-embedded sections were stained with hematoxylin and eosin and elastin/van 
Gieson (Sigma) for histological evaluation using an Olympus U-ULH optical microscope (Olympus 
Optical Co. Ltd, Tokyo, Japan). Image-Pro Plus TM software version 4.0 (Media Cybernetics, Silver 
Spring, USA) was used to trace the external elastic lamina, internal elastic lamina, and lumen in the 
aortic root area to ascertain the area of atherosclerotic lesions. The total aortic root area and lesion 
area were measured following which the ratio of total lesion area/total aortic root area was calculated 
and expressed as percentage of lesion in the aortic root area. Collagen was detected using Sirius 





with proximal aortas embedded in OCT were sectioned and fixed in methanol. Consecutive 
tissue sections were incubated in 0.2% TritonX-100/phosphate-buffered saline (PBS) for 1 hour then 
blocked with 1% bovine serum albumin (BSA) for 1 hour. The samples were stained with either 
purified hamster anti-mouse CD11c (eBioscience, Ltd., Hatfield, UK) or rat anti-mouse CD4 (BD 
Biosciences, Oxford, UK), CD68, Foxp3, or TNF-  (BioLegend, San Diego, CA, USA) at 4°C 
overnight, washed in PBS and incubated with rabbit anti-rat IgG-fluorescein isothiocyanate (FITC) or 
goat anti-mouse IgG-tetramethylrhodamine-5-(and-6)-isothiocyanate (TRITC) (Sigma-Aldrich 
Company Ltd. Dorset, UK). For detection of IL-10 producing CD4
+ 
T cells and for Foxp3
+
-CD4 T-cells 
(BD Biosciences, UK), FITC-conjugated rat anti-mouse CD4 mAb and phycoerythrin (PE)-labeled 
anti-mouse IL-10 and Foxp3 (BioLegend, San Diego, CA, USA) were used. All slides were counter-
stained with mounting medium containing 4, 6-diamino-2-phenylindole (DAPI) (Vector Laboratories 
Inc., Peterborough, UK). Bright-field images were captured, scanned, and overlaid using an Axiovert 
 4 
S100 TV immunofluorescence microscope (Zeiss, Welwyn Garden City, UK) equipped with Plan-
NEOFLUAR objectives and a KTL/CCD-1300/Y/HS camera (Princeton Instruments, Buckinghamshire, 









 cells within the lesion were measured with a 
microscope using a magnification as indicated in the related figures and averaged in m
2
. Three 
sections from each animal (six animals from each group) were investigated. For C5a and C5aR 
staining, rabbit polyclonal anti-mouse C5a antibody (Abbiotec, LLC, CA92126 USA) and rat anti-
mouse C5aR monoclonal antibody (Thermo, Rockford, IL USA) were used. 
 
Plasma-lipoprotein Analysis 
Plasma total cholesterol, triacylglycerol, and high-density lipoprotein (HDL) were measured using the 
enzymatic colorimetric method in a P800 modular chemical analyzer (Roche Diagnostics, Mannheim, 
Germany)  through a service from the Department of Laboratory Medicine, University of Szeged, 
Hungary. Low-density lipoprotein (LDL) cholesterol was calculated according to the Friedewald 
formula:  
LDL concentration (mmol/L) = total cholesterol – (HDL + triacylglycerol  0.46). 
 
Measurement of Pro- and Anti-Inflammatory Cytokines 
Concentrations of murine cytokines IL-10, TGF-β, TNF- , and IFN-  were measured in plasma using 
ELISA kits following the manufacturer’s instructions (R&D systems, Abingdon, UK). IL-10 and TNF-  
levels in the lesions were quantified by immunohistochemical analyses and the ratio of IL-10 and 
TNF-  positive area/total lesion area, respectively, was measured and calculated by using Image-Pro 
Plus TM, version 4.0. 
 
Cytokine Production by Splenocytes After In Vitro Stimulation with ConA 
Spleens were homogenized by pressing through 70- m cell strainer and the cells recovered 
suspended in RPMI (denotes: Roswell Park Memorial Institute) 1640 complete medium supplemented 
with 10% fetal calf serum (FCS), 100-U/mL penicillin, and 100-μg/mL streptomycin. The cells were 
cultured for 48 h at 37°C in a humidified 5% CO2 incubator at a density of 1×10
6
 cells/0.1 mL 
medium/well of the 96-well plate with a serial 10-fold dilution of ConA (1–100 g/mL) (Sigma, Dorset, 
 5 
UK). Cytokine (IL-10, TGF-β, TNF- , and IFN- ) concentrations in the supernatant of stimulated 
spleen cells were tested using ELISA kits (R&D systems, Abingdon, UK) according to the 
manufacturer’s instructions. 
 
Antigen-specific Regulatory Function Assays 
Antigen-specific regulatory function assay experiments were performed as previously described [3,4], 
with some modifications. Treg cells (95% purity) were selected from spleen CD4
+
 T-cells of C5aR-P1-, 




 Treg isolation kit (Miltenyi 











 T-cells from spleens of mice that had received oral immunization with C5aR-P1-, 













) in the presence of 2×10
4 
APC (3000 rad irradiated splenocytes) per well, 
and stimulated with 1-μM C5aR peptides, with KLH controls, or without C5aR peptides. After 3 days of 
culture, cells were pulsed with 0.5 μCi of [
3
H]thymidine (Amersham, Buckinghamshire, UK) for the last 
18 hours of culture, were harvested, and the incorporation of [
3
H]thymidine was determined using a 




 T-Cell Proliferation and Cytokine Secretion Assay  
CD4
+




J mice immunized with peptide 
antigens by using the magnetic-activated cell sorting CD4
+
 T-cell Isolation Kit (Miltenyi Biotec, Surrey, 
UK) and used as responder cells. C5aR-P1 (amino acids 1–21) and C5aR-P2 (amino acids 19–31) 









/well) were starved for 48 hours with serum-free 
culture medium, and then stimulated with -irradiated spleen cells (2x10
5
/well) in the presence of 
antigens or unrelated antigens (0–10 µM) for 72 h at 37°C in a 5% CO2, 95% air-humidified incubator. 
Cells were pulsed with 0.5 μCi of methyl-[
3
H]-thymidine (Amersham Biosciences, Amersham, UK)/well 
for the last 18 hours of culture on day 5. Proliferation was measured as [
3
H]TdR incorporation by 
liquid scintillation spectroscopy. Cytokine IFN-γ and IL-10 in the supernatant were measured using an 
ELISA kit.  
 
 6 
Peripheral Blood Mononuclear Cell (PBMC) Isolation From C57BL/6 Background Mice 
Blood taken from C57/BL6 background mice was diluted with PBS (1:4 dilution) and slowly layered 
over pre-prepared histopaque solution (1:1 v/v) in a centrifuge tube, followed by centrifugation (2000 
rpm) at room temperature for 20 minutes to collect the mononuclear cells retained at the surface of 
histopaque solution. The isolated PBMCs were used for further flow cytometric analysis for their 
differentiation.  
 
Flow Cytometric Analysis 




J mice were used for determination 
of CD206, a macrophage marker or PBMC from the naïve mice (C57/B6 back ground) for 
determination of CD206 as well as F4/80, a monocyte/macrophage marker (differentiation was 
observed by measuring the increased numbers of macrophages) by flow cytometric analysis. Briefly, 
3×10
5
 cells were incubated at 4°C for 30 min with appropriate dilutions of directly labeled monoclonal 
antibodies (allophycocyanin–anti-mouse CD206 antibody; BioLegend, Cambridge, UK) and FITC-anti-
mouse F4/80 antibody (eBioscience, Hatfield, UK). After 2 washing steps with 0.02% BSA/PBS (pH 
7.3), fluorescence was analyzed on a flow cytometer (Cytomics FC500; Bachman coulter, High 
Wycombe, UK). Six mice were used in each experimental group. For the measurement of C5aR 
concentration in the plasma, PE anti-mouse CD88 (C5aR) antibody (BioLegend UK Ltd, Cambridge, 
UK) was used according to manufacturer’s protocols. For Treg detection, spleen cells from mice 
immunized with either C5aR peptides or KLH (control) were performed using a Treg detection kit 
(Miltenyi Biotec, Surrey, UK) according to manufacturer’s protocols. 
 
Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis 
Total RNA from the aortic arch was isolated using TRIzol® reagent (Invitrogen, Carlsbad, California, 
USA). The quality of the RNA was determined by measuring the absorbance at 230, 260, and 280 nm 
using Nanodrop 1000. RT-PCR was performed with a 2-step SYBR superscript RT-PCR kit 
(Invitrogen) using the ABI PRISM 7500 sequence detection system (Applied Biosystems, 7500 real 
time PCR system). Mouse GAPDH was used to normalize sample amplification. The following mouse-
specific primers were used to amplify the desired genes: 
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IL-10-F, 5’- GCTCTTACTGACTGGCATGAG-3'; IL-10-R, 5'-CGCAGCTCTAGGAGCATGTG-3'; TGF-
-F, 5’- TTGCTTCAGCTCCACAGAGA-3’; TGF- -R, 5’- TGGTTGTAGAGGGCAAGGAC-3’ 
IFN- -F, 5’-ATGAACGCTACACACTGCATC-3’; IFN- -R, 5’-CCATCCTTTTGCCAGTTCCTC-3’ 
TNF-α-F, 5'-ATGAGCACAGAAAGCATGATC-3'; TNF-α-R, 5'-TACAGGCTTGTCACTCGAATT-3' 
GAPDH-F, 5’ AACTTTGGCATTGTGGAAGG-3’; GAPDH-R, 5’-ACACATTGGGGGTAGGAACA-3’ 
 
For Foxp3 gene expression analysis in lymph nodes, the primers were used to amplify the Foxp3 
gene: Foxp3-F, CCCATCCCCAGGAGTCTTG-3’; Foxp3-R, ACCATGACTAGGGGCACTGTA-3’ 
Data were analyzed on the basis of the relative expression method with the formula: 
 





EP refers to efficiency as defined by Pfaffl [5] and is determined for the primer set that amplifies the 
target sequence (EP-target) and the primer set that amplifies the housekeeping sequence (EP-housekeeping). 
The term ∆CT-target denotes the difference in CT values between the control and treatment (CT-control – 
CT-treatment) for the target sequence and the term ∆CT -housekeeping refers to the difference in CT values 
between the control and treatment (CT control – CT treatment) for the housekeeping sequence. 
 
Statistical Analyses  
Data are reported as mean±standard error of the mean (±SEM), unless otherwise indicated. Figures 
were plotted using graph-pad Prism 5.01 and Sigma plot 9.0. For atherosclerotic lesion size, data 
were compared and intergroup differences were conducted using one-way ANOVA for multiple 
comparisons and post hoc bonferroni test. Others data were analyzed using Student’s t-test (2-tailed 
analyses). Non-parametric distributions were analysized using Mann-Whitney U test for paiwise 
comparisons and the Kruskal-Wallis test for multiple comparisons. Differences between groups 
were considered significant at P values below 0.05. 
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Supplementary Figure Legends 
 
Figure I. (A) Representative photomicrographs showing immunohistochemical staining of the aortic root 
showed C5aR
+
 cells (red) and C5a
+
 area (green) in the lesion, and C5aR
+
 cells co-localized within C5a
+
 
(yellow) in lesions from C5aR-peptide-immunized mice and KLH-immunized mice. (B) and (C) Quantitative 
















 cells. (F-H) Assessment of C5a and C5aR 




J mice fed a high-fat diet after immunization with an ApoB 
peptide, human heat-shock protein (HHSP)60 peptide, and a combination of ApoB and HHSP60 peptides in 
KLH-conjugated form, compared with KLH control (reference 2). (F) Representative photomicrographs 
showing immunohistochemical staining of C5aR (in red), C5a (in green), and merged C5a/C5aR. (G) C5aR-
positive area in lesion. (H) Percent of C5aR-occupied lesion. (n=6 mice) 
 
Figure II. (A) Measurement of cross-reaction using C5aR-P1- or C5aR-P2-immunized serum to react with 
oxLDL and native LDL. The immunized mice used were fed with normal chow for 5 weeks. (B) Measurement 
of cross-reaction using pooled ApoB-peptide-immunized mice serum to react with C5aR peptides. Blood 
samples were taken from the immunized mice at 4 weeks after the first injection of the antigens to test cross-
reaction. (C) C5a concentrations in plasma observed by ELISA analysis (n=6 mice). (D) OxLDL 
concentrations in plasma observed by ELISA analysis (n=5 mice). (E) C5aR expression in lymph nodes 
analyzed by flow cytometer. 
 
Figure III. Cytokine mRNA expression in aorta arch and Foxp3 mRNA expression in lymph nodes, 
respectively; Real-time reverse-transcription PCR normalized to GAPDH in aorta arches and lymph 
nodes of peptide-immunized mice. (A) Showing fold of increase in expression levels considering the 
expression in control as 1-fold; (B) IL-10, (C) TGF- , (D) TNF-  and (E) IFN-  expression (relative to GAPDH) 
in aorta arches of mice treated with C5aR-P1 and C5aR-P2 either singly or in combination. (F) Showing fold 
of increasing or decreasing expression levels considering the expression in control as 1-fold. Values are 
means ± SEM from 5 mice per group. *P<0.05. 
 
Figure IV. Analysis of peptide antigen epitope-induced specific CD4
+




T cells isolated from the splenocytes of mice were incubated with the peptide at the dose of 0.01–10 
µM/L in the presence of irradiated stimulator spleen cells. (A) CD4
+
 T-cells from C5aR-P1-immunized mice 
stimulated with C5aR-P1 peptide and with C5aR-P2 peptide. (B) CD4
+
 T-cells from C5aR-P2-immunized mice 
stimulated with C5aR-P2 peptide and with C5aR-P1 peptide. (C) CD4
+
 T-cells from a combination of C5aR-
P1 and C5aR-P2-immunized mice stimulated with either C5aR-P1 or C5aR-P2 peptides. (D) CD4
+
 T-cells 














     
  

















         







                          
      
 
   





        
                 
 
                    
              





 Table 1. Lipid concentrations in plasma and body weight of peptide-immunized mice 
 







with HFD for 
















immunized mice  10 
 
 





immunized mice  10 
 




















1. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, 
McIntyre GD. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma. 
1997; 16:381-389. 
2. Lu X, Chen D, Endresz V, Xia M, Faludi I, Burian K, Szabo A, Csanadi A, Miczak A, Gonczol E, 
Kakkar V. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early 
atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice. Atherosclerosis. 2010; 212:472-480.  
3. Herbin O, Ait-Oufella H, Yu W, Fredrikson GN, Aubier B, Perez N, Barateau V, Nilsson J, Tedgui A, 
Mallat Z. Regulatory T-cell response to apolipoprotein b100-derived peptides reduces the 
development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:605-
612. 
4. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, Ketelhuth DF, 
Gerdes N, Holmgren J, Nilsson J, Hansson GK. Intranasal immunization with an apolipoprotein B-100 
fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler 
Thromb Vasc Biol. 2010;30:946-952. 





         
